责任编辑：觅健科普君
封面图片来源：摄图网 稿定设计
[1] Allemani, C., Matsuda, T., Di Carlo, V., Harewood, R., Matz, M., Nikšić, M., Bonaventure, A., Valkov, M., Johnson, C. J., Estève, J., Ogunbiyi, O. J., Azevedo E Silva, G., Chen, W. Q., Eser, S., Engholm, G., Stiller, C. A., Monnereau, A., Woods, R. R., Visser, O., Lim, G. H., … CONCORD Working Group (2018). Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet (London, England), 391(10125), 1023–1075. https://doi.org/10.1016/S0140-6736(17)33326-3
[2] Connolly, D., Black, A., Gavin, A., Keane, P. F., & Murray, L. J. (2008). Baseline prostate-specific antigen level and risk of prostate cancer and prostate-specific mortality: diagnosis is dependent on the intensity of investigation. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 17(2), 271–278. https://doi.org/10.1158/1055-9965.EPI-07-0515
[3] 中华医学会泌尿外科学分会. 科学出版社，2022.
[4] King C. R. (2016). The dose-response of salvage radiotherapy following radical prostatectomy: A systematic review and meta-analysis. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 121(2), 199–203. https://doi.org/10.1016/j.radonc.2016.10.026
[5] https://www.urotoday.com.
[6] Kazama, A., Saito, T., Takeda, K., Kobayashi, K., Tanikawa, T., Kanemoto, A., Ayukawa, F., Matsumoto, Y., Sugita, T., Hara, N., & Tomita, Y. (2019). Achieving PSA < 0.2 ng/ml before Radiation Therapy Is a Strong Predictor of Treatment Success in Patients with High-Risk Locally Advanced Prostate Cancer. Prostate cancer, 2019, 4050352. https://doi.org/10.1155/2019/4050352
[7] Kim, M., Lee, J., Jeong, C. W., Ku, J. H., Kim, H. H., & Kwak, C. (2015). Prostate-specific antigen kinetic profiles during androgen deprivation therapy as prognostic factors in castration-resistant prostate cancer. Urologic oncology, 33(5), 203.e1–203.e2039. https://doi.org/10.1016/j.urolonc.2015.01.017
[8] Guin, S., Liaw, B. K., Jun, T., Ayers, K., Patel, B., O'Connell, T., Deitz, M., Klein, M., Mullaney, T., Prentice, T., Newman, S., Fink, M., Zhou, X., Schadt, E. E., Chen, R., & Oh, W. K. (2022). Management of de novo metastatic hormone-sensitive prostate cancer: A comprehensive report of a single-center experience. PloS one, 17(8), e0264800. https://doi.org/10.1371/journal.pone.0264800
[9]Tourinho-Barbosa, R., Srougi, V., Nunes-Silva, I., Baghdadi, M., Rembeyo, G., Eiffel, S. S., Barret, E., Rozet, F., Galiano, M., Cathelineau, X., & Sanchez-Salas, R. (2018). Biochemical recurrence after radical prostatectomy: what does it mean?. International braz j urol : official journal of the Brazilian Society of Urology, 44(1), 14–21. https://doi.org/10.1590/S1677-5538.IBJU.2016.0656
[10]Shah, T. T., Reddy, D., Peters, M., Ball, D., Kim, N. H., Gomez, E. G., Miah, S., Evans, D. E., Guillaumier, S., van Rossum, P. S. N., Van Son, M. J., Hosking-Jervis, F., Dudderidge, T., Hindley, R., Emara, A., McCracken, S., Greene, D., Nigam, R., McCartan, N., Valerio, M., … Winkler, M. (2021). Focal therapy compared to radical prostatectomy for non-metastatic prostate cancer: a propensity score-matched study. Prostate cancer and prostatic diseases, 24(2), 567–574. https://doi.org/10.1038/s41391-020-00315-y
[11]Aparicio A. (2023). Biochemical Recurrence in Prostate Cancer - Tilting the Scale. The New England journal of medicine, 389(16), 1522–1523. [12]https://doi.org/10.1056/NEJMe2309502
[13]https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6988964/
[14]中国医师协会放射肿瘤治疗医师分会，中华医学会放射肿瘤治疗学分会，中国抗癌协会肿瘤放射治疗专业委员会.，中华肿瘤防治杂志.2021.28(5):323-337.
[15]Cookson MS, Aus G，Burentt AL，et al. Variation in thedefinition of biochemical recurrence in patients treated for localized prostatecancer: the American Urological Association Prostate Guidelines for LocalizedProstate Cancer Update Panel report and recommendations for a standard in thereporting of surgical outcomes[J]. J Urol, 2007, 177(2): 540-545.
[16] Freedland SJ, Moul JW. Prostatespecific antigen definitive therapy[J]. J Urol, 2007, 177(6):1985-1991.
[17] Simmons MN, Stephenson AJ, Klein EA.Natural history of biochemical recurrence after radical prostatectomy: riskassessment for secondary therapy[J]. Eur Urol, 2007, 51(5): 1175-1184.
[18]Touma NJ, Izawa JI, Chin JL. Currentstatus of local salvage therapies following radiation failure for prostatecancer[J]. J Urol, 2005, 173:373-379.
